Generics in the United States Research Report by Size, Growth, Major Segments, and Leading Players

HTF Market Intelligence released a new research report of 34 pages on title ‘Generics in the United States’  with detailed analysis, forecast and strategies.


Generics in the United States industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Findings

– Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in the United States

– Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in the United States

– Leading company profiles reveal details of key generics market players’ global operations and financial performance

– Add weight to presentations and pitches by understanding the future growth prospects of the United States generics market with five year forecasts by both value and volume


Essential resource for top-line data and analysis covering the United States generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Make an enquiry before buying this Report @

Reasons To Buy

– What was the size of the United States generics market by value in 2016?

– What will be the size of the United States generics market in 2021?

– What factors are affecting the strength of competition in the United States generics market?

– How has the market performed over the last five years?

– How large is the United States’ generics market in relation to its regional counterparts?

Key Highlights

For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the ‘generic-eligible’ market, are not included.

The US generics market is expected to generate total revenues of $99.7bn in 2016, representing a compound annual growth rate (CAGR) of 7.9% between 2012 and 2016.

Market consumption volume is forecast to increase with a CAGR of 2% between 2012 and 2016, to reach a total of 86.2% of total pharma volume in 2016

In the US, generic drugs have led to annual savings of $227bn in 2015. Annual savings have grown by over 300% in the last decade.

Read Detailed Table of Content @

Executive Summary

Market value

Market value forecast

Market volume

Market volume forecast

Geography segmentation

Market rivalry

Market Overview

Market definition

Market analysis

Market Data

Market value

Market volume

Market Segmentation

Geography segmentation

Market Outlook

Market value forecast

Market volume forecast

Five Forces Analysis


Buyer power

Supplier power

New entrants

Threat of substitutes

Degree of rivalry

Leading Companies

Allergan plc

Mylan Inc.

Sandoz International GmbH

Teva Pharmaceutical Industries Limited

Macroeconomic Indicators

Country data


Industry associations


Buy this report @

Contact Us:

CRAIG FRANCIS (PR & Marketing Manager)

Ph: +1 (206) 317 1218

%d bloggers like this: